Patient and transplant characteristics for study group and matched cohort
| . | HCT patients . | . | ||
|---|---|---|---|---|
| Measure . | All, n = 57 (%) . | Blinatumomab n = 21 (%) . | Controls n = 36 (%) . | P value* . |
| Gender | ||||
| Male | 33 (58) | 17 (81) | 16 (44) | .012 |
| Female | 24 (42) | 4 (19) | 20 (56) | |
| Age in years, median (range) | 38.0 (16.0-66.0) | 29.0 (16.0-65.0) | 41.0 (19.0-66.0) | .26† |
| Race/ethnicity | ||||
| White | 36 (65) | 13 (62) | 23 (68) | .13 |
| Hispanic | 15 (27) | 8 (38) | 7 (21) | |
| Other | 4 (7) | 0 (0) | 4 (12) | |
| High cytogenetic/molecular risk | 49 (89) | 18 (90) | 31 (89) | 1.00 |
| Months from diagnosis to HCT | ||||
| Median (range) | 7.8 (2.9-107.7) | 8.8 (3.2-107.7) | 7.0 (2.9-99.8) | .25† |
| Disease status at HCT | ||||
| CR 1 | 32 (56) | 11 (52) | 21 (58) | .86 |
| CR 2 | 18 (32) | 7 (33) | 11 (31) | |
| CR 3+ | 7 (12) | 3 (14) | 4 (11) | |
| MRD at HCT | ||||
| Detected | 10 (18) | 4 (20) | 6 (17) | .73 |
| Not detected | 46 (82) | 16 (80) | 30 (83) | |
| Unknown | 1 | 1 | 0 | |
| Karnofsky performance status | ||||
| ≤80 | 5 (11) | 1 (6) | 4 (13) | .65 |
| ≥80 | 42 (89) | 15 (94) | 27 (87) | |
| HCT-CI | ||||
| Median (Range) | 3.0 (0.0-8.0) | 3.0 (0.0-8.0) | 3.0 (0.0-8.0) | .91† |
| Donor type | ||||
| MRD | 22 (39) | 7 (33) | 15 (42) | .48 |
| MUD | 21 (37) | 10 (48) | 11 (31) | |
| Haplo | 14 (25) | 4 (19) | 10 (28) | |
| Conditioning regimen | ||||
| MAC | 25 (44) | 4 (19) | 21 (58) | .010 |
| MAC/TBI | 8 (14) | 5 (24) | 3 (8) | |
| RIC | 24 (42) | 12 (57) | 12 (33) | |
| . | HCT patients . | . | ||
|---|---|---|---|---|
| Measure . | All, n = 57 (%) . | Blinatumomab n = 21 (%) . | Controls n = 36 (%) . | P value* . |
| Gender | ||||
| Male | 33 (58) | 17 (81) | 16 (44) | .012 |
| Female | 24 (42) | 4 (19) | 20 (56) | |
| Age in years, median (range) | 38.0 (16.0-66.0) | 29.0 (16.0-65.0) | 41.0 (19.0-66.0) | .26† |
| Race/ethnicity | ||||
| White | 36 (65) | 13 (62) | 23 (68) | .13 |
| Hispanic | 15 (27) | 8 (38) | 7 (21) | |
| Other | 4 (7) | 0 (0) | 4 (12) | |
| High cytogenetic/molecular risk | 49 (89) | 18 (90) | 31 (89) | 1.00 |
| Months from diagnosis to HCT | ||||
| Median (range) | 7.8 (2.9-107.7) | 8.8 (3.2-107.7) | 7.0 (2.9-99.8) | .25† |
| Disease status at HCT | ||||
| CR 1 | 32 (56) | 11 (52) | 21 (58) | .86 |
| CR 2 | 18 (32) | 7 (33) | 11 (31) | |
| CR 3+ | 7 (12) | 3 (14) | 4 (11) | |
| MRD at HCT | ||||
| Detected | 10 (18) | 4 (20) | 6 (17) | .73 |
| Not detected | 46 (82) | 16 (80) | 30 (83) | |
| Unknown | 1 | 1 | 0 | |
| Karnofsky performance status | ||||
| ≤80 | 5 (11) | 1 (6) | 4 (13) | .65 |
| ≥80 | 42 (89) | 15 (94) | 27 (87) | |
| HCT-CI | ||||
| Median (Range) | 3.0 (0.0-8.0) | 3.0 (0.0-8.0) | 3.0 (0.0-8.0) | .91† |
| Donor type | ||||
| MRD | 22 (39) | 7 (33) | 15 (42) | .48 |
| MUD | 21 (37) | 10 (48) | 11 (31) | |
| Haplo | 14 (25) | 4 (19) | 10 (28) | |
| Conditioning regimen | ||||
| MAC | 25 (44) | 4 (19) | 21 (58) | .010 |
| MAC/TBI | 8 (14) | 5 (24) | 3 (8) | |
| RIC | 24 (42) | 12 (57) | 12 (33) | |